Efficiency of sirolimus delivery to the skin is dependent on administration route and formulation

Since sirolimus (rapamycin) was discovered as an inhibitor of mammalian/mechanistic target of rapamycin (mTOR), investigators have focused on its potential as an anti-tumor drug because mTOR signaling controls complex cellular processes, including protein synthesis, cell cycle, and cell growth, and is frequently hyperactivated in tumor tissues [1]. Tuberous sclerosis complex (TSC) is an autosomal-dominant disease that results in hamartoma formation in almost all organs, including brain, heart, kidney, lung, and skin.

Source: Journal of Dermatological Science - May 12, 2019 Category: Dermatology Authors: Kazuko Kitayama, Shinichiro Maeda, Ayumi Nakamura, Ichiro Katayama, Mari Wataya-Kaneda Tags: Letter to the Editor Source Type: research